Karolinska Development's portfolio company Umecrine Cognitio

Karolinska Development's portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary cholangitis

STOCKHOLM, SWEDEN – April 17, 2023. Karolinska Development AB today announces that its portfolio company Umecrine Cognition has included the first patient in a Phase 2 clinical trial of the... | April 17, 2023

Related Keywords

Stockholm , Sweden , Karolinska Institutet , Viktor Drvota , Johan Dighed , Karolinska Development Ab Nasdaq Stockholm , Karolinska Development , Nasdaq Stockholm , Umecrine Cognition , General Counsel , Karolinska Development Ab Publ Stock Exchange , News , Information , Press Release , Pril , Karolinska , Development , Tb , Oday , Nnounces , Hat , Its , Portfolio , Company , Mecrine , Cognition , Gas , Ncluded , The , First , Patient , N , Hase , , Linical , Trial , F Kdev Se0002190926 ,